Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act for AR-301, a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically ill hospitalized patients.
Related news for (ARDS)
- Aridis Provides Corporate Update
- Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
- Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
- Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
- Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV